Skip to main content
Back to Grants Directory
OpenBusiness

Collaborate with the Functional

MRC · United Kingdom

Opportunity to collaborate with the Functional Genomics Screening Laboratory (FGSL) on projects using complex human in vitro models for CRISPR screening to better understand model biology and enable target identification.

Overview

Opportunity to collaborate with the Functional Genomics Screening Laboratory (FGSL) on projects using complex human in vitro models for CRISPR screening to better understand model biology and enable target identification.

Grant details

Application Platform: Application form submitted through Connect: Health Tech at the University of Cambridge and emailed to the programme team.

Application Sections: Application form including details about the in vitro model, desired screen, and endpoint assay.

Assessment Process: Applications are assessed by a Joint Steering Committee with representatives from MRC, AstraZeneca, and the Milner Therapeutics Institute.

Co-Funders: AstraZeneca; University of Cambridge

Collaboration Rules: Projects must be collaborative with the Functional Genomics Screening Laboratory. Screens are carried out by scientists at the Milner Therapeutics Institute but conducted in collaboration with the proposing research team.

Competitiveness: Not specified

Consortium Requirements: Not specified

Decision Risks: Applications may be rejected if the proposed biological model is unsuitable for CRISPR screening or if feasibility requirements are not met.

Decision Timeline: Applications are reviewed approximately twice per year by the Joint Steering Committee.

Eligible Expenses: Consumables for screens may be funded either by AstraZeneca where the model is of interest to AstraZeneca or through a screening access fund provided by MRC.

Eligible Scope: Projects using complex human in vitro models to conduct arrayed CRISPR screening for biological investigation and target identification.

Funding Intensity: Not specified

Important Notes: The Functional Genomics Screening Laboratory is a joint initiative between MRC, AstraZeneca, and the Milner Therapeutics Institute to provide access to advanced CRISPR screening capabilities for UK researchers.

Ineligible Projects: Not specified

International Collaboration Requirement: Not specified

Interview Stage: Not specified

Key Requirements: Applicants must provide detailed information about the model used, screening design, and endpoint assays.

Lead Organisation Requirement: Not specified

Match Funding Requirement: Not specified

Project Duration: Determined on a case-by-case basis depending on the model, its expansion capacity, and the size of the proposed screen

Project End Date: Not specified

Project Start Date: Not specified

Publication Date: 2024-04-18 00:00:00

Renewal Rules: Not specified

Research Category: Functional genomics research collaboration.

Research Organisation Funding: Not specified

Subcontractors: Not specified

Total Fund Available: Not specified

Quick facts

Status
Open
Closing date
Rolling
Funding amount
Amount not specified
Funding type
Procurement/Other
Audience
Business
Industry
Health & Life Sciences, Creative & Cultural

Official link